Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
Merck and Daiichi Sankyo pull their US lung cancer drug application following regulatory pushback.
Velocity
How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →
📍 How it ended
Merck and Daiichi Sankyo voluntarily retracted and scraped their FDA accelerated approval application and biologics license application for their partnered B7-H3 antibody-drug conjugate in previously treated extensive-stage small-cell lung cancer. This withdrawal followed regulatory pushback, marking another blow to their four-billion-dollar deal and prompting analysis regarding the valuation of Daiichi Sankyo Company.
Epilogue added 47d ago, after coverage quieted.
The brief
Recent coverage from BioSpace, FirstWord, simplywall.st, Endpoints News, OncLive, Reuters, and Fierce Biotech details that Merck and Daiichi Sankyo have voluntarily withdrawn their accelerated approval request and biologics license application for ifinatamab deruxtecan in previously treated extensive-stage small cell lung cancer. This regulatory setback follows pushback from the United States Food and Drug Administration. The withdrawn application represents the second partnered cancer therapy application pulled by the companies, creating further challenges for their multi-billion dollar partnership. Media reports and analytical commentary emphasize the significance of this development for the companies' joint oncology pipeline.
Publications such as FirstWord and Fierce Biotech frame the withdrawal as another major obstacle following previous difficulties in their alliance. Financial commentary from simplywall.st questions the valuation implications for Daiichi Sankyo Company following the regulatory setback, while OncLive and Endpoints News provide specific clinical context regarding the target, identifying the therapy as a B7-H3 antibody-drug conjugate. Context provided across the reporting highlights that this application withdrawal directly impacts the broad partnership between the two pharmaceutical firms. The overarching alliance, valued in the coverage at four billion dollars, has faced repeated hurdles regarding regulatory approvals for its antibody-drug conjugate assets.
While prior coverage does not yet specify the exact nature of the regulatory feedback or the precise clinical data points that triggered the Food and Drug Administration pushback, the voluntary withdrawal effectively halts the current review process for this specific indication. Looking ahead, coverage does not yet specify whether the companies intend to resubmit the application or pursue alternative clinical pathways for ifinatamab deruxtecan. Observers and market participants will monitor upcoming corporate communications from Merck and Daiichi Sankyo for further details regarding the future of their shared oncology portfolio and the broader implications for their multi-billion dollar collaboration agreement following this dual setback.
Synthesized by PULSE from the headlines below under a strict no-invention contract. ✓ fact-checked: all claims supported by sources Updated 48d ago.
Quick answers
Which companies are involved in the withdrawn application?
Merck and Daiichi Sankyo are the partners involved in the application.
What specific drug and indication were targeted?
The application involved ifinatamab deruxtecan, a B7-H3 antibody-drug conjugate for previously treated extensive-stage small cell lung cancer.
What outlets covered the trend?
Coverage was provided by BioSpace, FirstWord, simplywall.st, Endpoints News, OncLive, Reuters, and Fierce Biotech.
Coverage (7)
- Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC BioSpace · 51d ago
- Vital Signs: Twice bitten, thrice shy for Merck and Daiichi's ADC aspirations FirstWord · 51d ago
- Is Daiichi Sankyo Company (TSE:4568) Undervalued On Its FDA Filing Withdrawal? simplywall.st · 51d ago
- Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer Endpoints News · 51d ago
- Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC OncLive · 51d ago
- Merck, Daiichi pull US application for second partnered cancer therapy Reuters · 51d ago
- Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal Fierce Biotech · 51d ago
Topics
Related trends
Roche Secures First U.S. Approval for New Breast-Cancer Pill
Roche wins FDA approval for its first U.S. oral SERD, giredestrant plus everolimus, for hormone-resistant advanced breast cancer.
Biotech Tops The 'Most Bullish Conversations' And Breaks Out
Biotech markets surge in bullish conversations amid major trial outcomes and regulatory updates from key industry players.
Novo says Wegovy injection lowers BMI and obesity rates in children in trial
Novo Nordisk reports Wegovy injection reduced BMI and obesity rates in children as young as six in a clinical trial, expanding the drug's potential pediatric use.
The GLP-1 boom has a dark side
FDA orders new eye-risk warnings on a dozen GLP-1 drugs, including Ozempic and Zepbound, amid reports of vision-threatening events.
Johnson & Johnson looking to buy eye disease biotech for up to $3.4bn
Johnson & Johnson agreed to buy Texas-based biotech Ollin Biosciences for up to $3.33 billion to expand its eye disease therapies.
Millions of Americans are not taking their GLP-1 drugs as prescribed
Nearly half of U.S. GLP-1 users are altering prescribed dosing, with cost and side effects driving widespread non-adherence.